Cusatuzumab for treatment of CD70‐positive relapsed or refractory cutaneous T‐cell lymphoma

Abstract

Cusatuzumab was well tolerated, and antitumor activity was observed at both 1 and 5 mg/kg in highly pretreated patients with R/R CTCL. The observed dose-dependent effect on exposure supports the use of 5 mg/kg for future development.